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Inkjet Based Personalized Screening Platform for Cancer Therapy

ABSTRACT
by
JORGE IVÁN RODRÍGUEZ DÉVORA
The new paradigm of personalized medicine is beginning to affect clinical practice. In
particular, many of the advances in genomics and proteomics have made personalized
screening and therapeutic inventions possible. On chip, cellomics approaches to
screening and intervention are becoming more commonplace. Cancer therapies may
benefit from the rise in ‘-omics’ technologies. In addition, the availability of rapid
screening data is crucial to mitigate cancer propagation and increase the possibility of
patient recovery. This study is an endeavor to develop a cellomic anticancer drug
screening process based on inkjet printing. Previous research has demonstrated that
inkjet based screening can reliably create isolated spots arrays at low volume (180 pl)
and high throughput (213 spots/sec). Herein we study whether inkjet printing small
volumes of anticancer drugs along with few cells has merit as a tool to fabricate cellomic
chips. Inkjet printing has the potential to minimize drug use and maximize the use of cell
biopsies.
Cells, from the hepatocellular carcinoma line HepG2 and the epithelial cell line PHEC,
were printed with an inkjet device and thus arrayed on a 96-well plate for culture. The
inkjet device was described before [1]. At mean exponential proliferation rate,
vi

cyclophosphamide monohydrate (Cytoxan) and dichloroacetate sodium (DCA) at
standard chemotherapeutic concentrations in the range of 1-50 mM were printed at
continuously increasing densities in order to expose cultures to a drug concentration
gradient. Anticancer drugs were studied under two solvents by means of dimethyl
sulfoxide and PBS. The printed volumes were in the nanoliter range accounting for 625
± 20% cells per spot. MTS assay was utilized to determine the amount of viable cells
upon 24 hours of drug exposure followed by 48 hours for cell recovery. Half maximal
and 90 percent inhibitory concentrations (IC50, IC90) were obtained from the doseresponse curve. Along with the proposed cellomic chip, a screening platform using
traditional micropipetting technique was built to compare results and validate inkjet
based screening platform applicability.
Results obtained show that both cell lines were growth inhibited under both drug
regimens.

The IC50 values obtained by micropipetting and inkjet based screening

varied less than 1mM suggesting that the proposed screening platform closely mimics
the traditional screening outcome. However the IC90 values obtained vary in the range
of 1 to 4.5 mM. The resulted IC50 indicates that 9.35 and 4.3 mM will be sufficient to
inhibit growth of both cell lines under cytoxan and DCA treatment, respectively. In
comparison to literature, IC50 results vary based on the cell lines used for the screening
platform, but are generally in the range of 4-10 mM. Thus our results are consistent
with those that used much larger volumes, validating our hypothesis that screening
assays can be further miniaturized.

vii

Inkjet technology shows promise to be used to determine dosages and treatment
modalities using the patient’s limited supply of biopsied cells. Expansion of the
screening process to more drugs and usage of actual patients’ biopsied cancer cells will
result in valuable data to forecast efficiency of potential drug therapies.
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CHAPTER 1: INTRODUCTION
1.1

Personalized Medicine
Personalized medicine has gained attention in public health due to the

continuous innovation in patient care. As a post-genomic era consequence,
personalized medicine has emerged as a tailoring of medical treatment to the individual
characteristics of each patient. This approach relies on scientific breakthroughs in the
understanding of how a person’s unique molecular and genetic profile makes them
susceptible to certain diseases. This research is increasing our ability to predict which
medical treatments will be safe and effective for each patient, and which ones will not
[2]. Figure 1 shows a comparison of traditional against personalized medicine where
treatment is improved by taking into account the particular onset conditions of the
patient.

Figure 1.Personalized Medicine[3].

Personalized medicine can be classified based on the analysis level whether the
focus be on cellomic (cytomic), proteomic, or genomic. While genomic and proteomic
1

approaches show more potential and scientific interest, due to the complexity of human
genetic information this branch need further develop to transform itself into a clinical
reality. One of the earliest and most common examples of personalized medicine at
proteomic level came in Herceptin® (trastuzumab). In about 30% of patients with breast
cancer over-express HER2, which is not responsive to standard therapy. Herceptin was
approved for patients with HER2 positive tumors in 1998 and further research in 2005
showed that it reduced recurrence by 52% in combination with chemotherapy [4].
On the cellomic (cytomic) approach, cells constitute the elementary function unit.
Diseases are caused by molecular changes in cells leading directly or indirectly to
altered molecular cell phenotypes as a result of genotype and exposure influences
during cell life. Cell phenotype changes may in a substantial number of instances be
more closely linked to the actual disease process in individual patients and to its future
development than either genomic

status

or environmental influences alone.

Understanding the root causes of complex diseases such as cancer is essential for
developing the most effective detection methods and for defining the most appropriate
treatment (and ultimately preventive) strategies. The detection of some of these
diseases has been greatly facilitated by the identification of diagnostic biomarkers, but
until very recently, this approach focused largely on single molecules. In addition, a
number of cancer therapies are targeted toward a specific molecule or signaling
pathway, to inhibit tumor growth. These approaches reflect the traditional scientific
approach of reducing cellular processes to their individual components and/or signal
transduction pathways. However, the behaviors of most biological systems, including
2

those affected in cancer, cannot be attributed to a single molecule or pathway, rather
they emerge as a result of interactions at multiple levels, and among many cellular
components [5].

1.1.1 Personalized Medicine in Cancer Therapy
Cancer is the most devastating disease and leading cause of death throughout
the world. Recent research has demonstrated that cancer has the greatest economic
impact from premature death and disability of all causes of death worldwide [6]. The
economic toll from cancer is nearly 20 percent higher than heart disease, the second
leading cause of economic loss ($895 billion and $753 billion respectively). There is an
increasing need for search of new compounds with selective cytotoxic effect on tumors
whereas current anticancer drugs are often unsatisfactory due to the secondary toxic
effect on healthy tissues. The lack of cancer-selective drugs and side effects tends to
cause that cancer treatment results in an iterative process. Anticancer drug treatment
prescribed by an oncologist depends on complex factors, such as type of cancer,
aggressiveness, patient’s weight, age, and physical condition, and often times based on
socio-economic factors. Traditional medicine is focus on treatments based on the “one
size fits all” model often neglecting individual on-set conditions that in some cases could
even aggravate the disease treatment [1]. On the other hand, personalized medicine
promises to refine diagnosis, guide optimum treatment, and avoid unnecessary side
effects. While current anticancer drugs are developed based on in vitro studies made
with commercially available cell lines, personalized medicine will require to study
patient’s own cells. In particular, there is need to develop miniaturized platforms to
3

analyze whether biopsied cancer cells are responsive to in vitro anticancer drugs to
determine the appropriate dosage and drug formulations for treatment.

1.2

Drug Discovery Screening Process
The availability of high-speed, miniaturized, low-cost, and high throughput

screening processes are very important issue in many fields such as drug discovery,
biosensing, stem cell research, genomics, environmental monitoring, forensic
investigation, and military defense [7, 8]. In drug discovery, surveys have been
conducted in USA indicating that drug discovery and development costs have been
rising. Although there are no fixed cost estimates, the most recent estimates stands at
US$ 802 million [9] spread over 12 years or US$ 880 million distributed over 15 years
[10] per single drug. A suggested probable reason for the rising in costs is that the new
compounds are hard to synthesized, which limits the amount of assays that can be
screen. Miniaturization of the screening process is required to optimize this process.

1.3

The Importance of Screening Process in Personalized Medicine
The pursuit of personalized medicine was one of the driving forces behind the

13-year, $3 billion Human Genome Project. Researchers hoped that once the genetic
blueprint was revealed, they could create DNA tests to gauge individuals' risk for
conditions like diabetes and cancer, allowing for targeted screening or preemptive
intervention. Genetic information would help doctors select the right drugs to treat
disease in a given patient. Such advances would dramatically improve medicine and

4

simultaneously lower costs by eliminating pointless treatments and reducing adverse
drug reactions.
Personalized medicine is a young but rapidly advancing field of healthcare that is
informed by each person's unique clinical, genetic, genomic, molecular, and
environmental information. Because these factors are different for every person, the
nature of diseases—including their onset, their course, and how they might respond to
drugs or other interventions—is as individual as the people who have them. It is about
making the treatment as individualized as the disease and involves identifying genetic,
genomic, molecular, and clinical information that allows accurate predictions to be made
about a person's susceptibility of developing disease, the course of disease, and its
response to treatment.
The 2003 sequencing of the human genome provided crucial insight into the
genetic foundations of countless medical conditions and scientists and physicians are
exploiting these foundations to advancing the field of personalized medicine. However,
it is not yet an established part of clinical practice, but nevertheless a number of top-tier
medical institutions now have personalized medicine programs, and many are actively
conducting both basic research and clinical studies in genomic medicine.
Specific advantages that personalized medicine may offer patients and clinicians
include:
•

Ability to make more informed medical decisions

•

Higher probability of desired outcomes thanks to better-targeted therapies
5

•

Reduced probability of negative side effects

•

Focus on prevention and prediction of disease rather than reaction to it

•

Earlier disease intervention than has been possible in the past

•

Reduced healthcare costs
To make personalized medicine a reality, better analytical tools are required to

effectively and accurately identify behavior, pathways, and genes that are related to a
certain disease in order to assess the patient’s risk. Combinatorial analysis of markers,
therapeutic drugs, dyes, living organisms, genes is a key to identifying potential
personalized treatment. Robotic equipment has been developed to execute such
analysis; however, research has been conducted in order to develop alternative
systems as current robotic systems are constraint to well-plate footprint at relatively high
volumes (microliter range). These systems must fulfill many design constraints,
including the capability of multiple cell dispensing, high throughput, effective utilization
of reagents, accuracy, and reproducibility of results.

1.4

Miniaturization - the Importance of Screening Volume
In high throughput screening (HTS), higher density lower volume assay plates

are

being

investigated

because

of

the

combined

effect

of

decreased

reagent/consumable and increased throughput (more assays per plate). For instance,
genomics research is pushing toward high density micro-array of DNA. The more DNA
‘spots’ that can be arrayed per slide, the more genetic variations can be investigated
[11]. Current well plates used for routine screening are in the range of 384 - 1,536 wells
6

utilizing 2.5 - 10 µl of reagents per well as shown in Figure 2. However, some studies
have already used 3,456-well plates and total assay volume of 1–2 µl [12], and robotic
systems have been developed to accurately and reproducibly pipette volumes as low as
25 nanoliters [13], while the standard 125.76 by 85.48 mm well-plate footprint has been
kept. Current trends identified on Figure 2 are: 1) Minimizing reagent volume, 2)
increase number of assays per day (throughput), 3) preserving footprint area of the wellplate.

Figure 2. Current trend towards screening miniaturization [14].

7

CHAPTER 2: LITERATURE REVIEW
2.1

Anticancer Therapy
The conventional approach to cancer therapy has been to provide treatment

according to the organ or tissue in which the cancer originates. This approach was
appropriate when there was only a rudimentary understanding of the molecular origins
of cancer and the different intracellular signaling pathways that are activated in the
various types of cancer. In the past two to three decades the genetic events that lead to
cancer have been elucidated. It has become clear that cancer develops as a result of
multiple genetic defects and that individuals with the same type of cancer often have
dissimilar genetic defects in their tumors. These findings explain why patients who seem
to have similar cancers respond in a heterogeneous manner to anticancer agents and
show the huge obstacle we are faced with to providing effective treatments for cancer.
Consequently, cancer therapy has slowly but steadily begun to shift from a ‘one size fits
all’ approach to a more personalized approach, in which each patient is treated
according to the specific genetic defects in the tumor. Such an individualized approach
requires the discovery and development of prognostic biomarkers that help doctors to
decide which patients to treat and predictive biomarkers that help in deciding which
therapy is most likely to be more effective for a given patient. By definition, prognostic
biomarkers predict the clinical outcome for a patient if no anticancer drugs are
administered, whereas predictive biomarkers predict the outcome of a specific therapy
for a patient. An example of why such biomarkers are needed to improve patient
management is that, for some tumors, resection of the primary tumor might be curative;
8

therefore, systemic therapy to eliminate any remaining tumor cells (also known as
adjuvant therapy) would not be needed. By contrast, for more malignant primary tumors,
aggressive systemic therapy, often chemotherapy, might be required after resection, in
order to reduce the risk of the tumor recurring. However, the distinction between these
is often unclear, so prognostic biomarkers that enable the likelihood of recurrence to be
determined are urgently needed in the clinic [15].

2.2

Cell Lines and Drugs Background
A recent report by the American Cancer Society (ACS) [16] has summarized the

facts of current cancer types affecting the United States. A list of common cancer types
includes cancers that are diagnosed with the greatest frequency, excluding nonmelanoma skin cancers:
•

Bladder Cancer

•

Lung Cancer

•

Breast Cancer

•

Melanoma

•

Colon and Rectal Cancer

•

Non-Hodgkin Lymphoma

•

Endometrial Cancer

•

Pancreatic Cancer

•

Kidney (Renal Cell) Cancer

•

Prostate Cancer
9

•

Leukemia

•

Thyroid Cancer
To qualify as a common cancer for the list, the estimated annual incidence for

2012 had to be 40,000 cases or more. Moreover, the following table gives the estimated
incidences and mortalities for each common cancer type:
Table 1. Incidence and mortality of common cancer types[17].

Cancer Type

Estimated New Cases

Estimated Deaths

Bladder

73,510

14,880

Breast (Female – Male)

226,870 – 2,190

39,510 – 410

Colon and Rectal

143,460

51,690

Endometrial

47,130

8,010

Kidney (Renal Cell) Cancer

59,588

12,484

Leukemia (All Types)

47,150

23,540

Lung (Including Bronchus)

226,160

160,340

Melanoma

76,250

9,180

Non-Hodgkin Lymphoma

70,130

18,940

Pancreatic

43,920

37,390

Prostate

241,740

28,170

Thyroid

56,460

1,780

(Combined)

10

The top 3 deadly cancer types are lung, colorectal, and breast cancers, while the
most incident cancer types are prostate, lung, and breast cancers. As reference some
similar statistics from previous years are presented in Appendix A.
2.2.1 Background of Cell Lines Studied
2.2.1.1

Human Hepatocellular Carcinoma Cell Line (HepG2)

Hepatitis B virus (HBV) is the major cause of acute and chronic hepatitis, leading
to progressive development of necroinflammatory changes in the liver, which can result
in cirrhosis and hepatocellular carcinoma. Although the development of an effective
vaccine to prevent HBV infection has shown promising results and should lead to its
eventual eradication, antiviral chemotherapy remains the only effective method to
prevent the progression of the disease in chronic carriers. Therefore, the development
of new antiretroviral agents active against HBV is needed. HepG2 cells have an
epithelial morphology and are thought to be a very useful model to study HBV virus
replication via transfection. Cells are also used for cancer and apoptosis studies (in
particular signaling pathway studies) (from abcam.com)
Hepatocellular carcinoma cells are perpetual, adherent, epithelial-like type cells,
which grow as monolayers and in small aggregates. HepG2 cell line was derived from
the liver tissue of 15-year-old Caucasian American male with differentiated
hepatocellular carcinoma. HepG2 is not tumorigenic in immunocompromised mice.
These cells secrete plasma proteins, such as albumin, transferrin, fibrinogen, a-2macroglobulin, and plasminogen. Cells respond to stimulation with HGH. The vast
11

amount of studies made with this cancer cell line make it ideal to have more information
available for discussion purposes. Doubling time: around 35 hours, from [18]. Figure 3
show a representative image of HepG2 culture in a petri dish.

A

B

Figure 3. Representative image of HepG2 cancer cells(A) and Epithelial cells (B) in a culture plate.

2.2.1.2

Epithelial Cell Line

Epithelial cells are bound together in sheets of tissue called epithelia. These
sheets are held together through several types of interactions, including tight junctions,
adherents, desmosomes, and gap junctions (Figure 4).One type of junction found only
in epithelium is the tight junction, which is considered by most scientists as the closest
junction in the world. Tight junctions act as the delineation between the apical (upper)
and basal (lower) regions of an epithelial cell in conjunction with polarization between
the two regions. Epithelium is supported on the basal side by a basement membrane
called the basal lamina. Below the basal lamina lies the capillary bed, which provides
epithelia with required nutrients and disposal of waste products. In addition, the nucleus
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in the epithelial cell is usually found closer to the basal surface than the apical
surface[19].

Figure 4. Epithelia are apical to the basement membrane and are characterized by the presence of tigh
junctions.

2.2.2 Anticancer drugs
Currently there are many anticancer drugs that are being commercialized for
cancer treatments and some others that are under investigation to be applied on clinical
therapies. A comprehensive review is given here [20-25]
In general, anticancer drugs have six dosing principles [26-28]:
1. Drugs: more effective in combination (may be synergistic)
2. More effective if drugs do not share common mechanisms of resistance.
3. More beneficial if drugs do not overlap in major toxicities.
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4. Drugs should be in administered near their maximum individual doses
5. Drugs should be administered as frequently as possible -- to maximize dose
intensity (dose per unit time) limiting tumor regrowth.
6. Desirable: maximum cell kill with each treatment cycle, using the highest dose
possible, repeating doses as frequently as tolerable.
These principles have to be in mind while pursuit the development of the current
anticancer screening.
2.2.2.1

Cyclophosphamide monohydrate

Cyclophosphamide (cytoxan) is an alkylating agent, a drug that is used primarily
for treating several types of cancer. It is used alone or in combination with other
medications to treat Hodgkin's lymphoma (Hodgkin's disease) and non-Hodgkin's
lymphoma (types of cancer that begin in a type of white blood cells that normally fights
infection); cutaneous T-cell lymphoma (CTCL, a group of cancers of the immune system
that first appear as skin rashes); multiple myeloma (a type of cancer of the bone
marrow); and certain types of leukemia (cancer of the white blood cells), including
chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute
myeloid leukemia (AML, ANLL), and acute lymphoblastic leukemia (ALL). It is also used
to treat retinoblastoma (cancer in the eye), neuroblastoma (a cancer that begins in
nerve cells and occurs mainly in children), ovarian cancer (cancer that begins in the
female

reproductive

organs

where

eggs

are

formed),

and

breast

cancer.

Cyclophosphamide is also used to treat nephrotic syndrome (a disease that is caused
by damage to the kidneys) in children whose disease has not improved, has gotten
14

worse, or has come back after taking other medications or in children who experienced
intolerable side effects with other medications [29].
When administrated in vivo, cyclophosphamide first is converted by the liver into
two chemicals, acrolein and phosphoramide, which are the active compounds that slow
the growth of cancer cells by alkylating DNA. When administrated in vitro,
cyclophosphamide interacts with the DNA primarily in site N7 position of guanine (other
sites as well). Interaction may involve single strands or both strands (cross linking, due
to bifunctional [2 reactive centers] characteristics) Other interactions: these drugs react
with carboxyl, sulfhydryl, amino, hydroxyl, and phosphate groups of other cellular
constituents. These drugs usually form a reactive intermediate -- ethyleneimonium ion
[30]. Unfortunately, normal cells also are affected, and this results in serious side
effects. In addition to slowing the growth of cancerous cells, cyclophosphamide also
suppresses

the

immune

system

and

bone

marrow,

it

is

referred

immunosuppressive. The FDA approved Cytoxan in November 1959 [31].

Figure 5. Cyclophosphamide formulation
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2.2.2.3

Dichloroacetate Acid

Early investigations focusing in the metabolic differences between cancer and
normal cells were made by Otto Warburg, who showed that cancer cells are inherently
dependent on glycolysis for production of chemical energy, ATP [32]. A key regulator of
cellular metabolism is pyruvate dehydrogenase (PDH), which governs the conversion of
pyruvate to acetyl Co-A and therefore, can control the flow of metabolites from
glycolysis to the citric acid cycle and subsequently the generation of ATP by
mitochondria. PDH is regulated by pyruvate dehydrogenase kinase (PDK) that
phosphorylates and inactivates PDH [33]. Dichloroacetate (DCA) inhibits PDK,
increasing the flux of pyruvate into the mitochondria, and has recently been proposed
as a novel and relatively non-toxic anti-cancer agent [34]. DCA has been shown to
reverse the glycolytic phenotype in a number of cancer cell lines, depolarizing the
hyperpolarized inner mitochondrial membrane potential to normal levels and increasing
mitochondrial metabolism [34, 35]. Because DCA targets a change undergone during
tumorogenesis, it can be effective against cancer cells without toxicity to normal cells.
DCA is currently in phase III clinical trials for the treatment of chronic lactic acidosis in
congenital mitochondrial disorders [36, 37], and thus has the potential to move quickly
into the clinic for other applications as it has passed phase I/II toxicity testing in humans
[38]. Clinical trials evaluating its toxicity in cancer patients are underway; however,
controlled experiments to understand the anti-cancer activities of DCA are needed to
determine which tumors and which patients are most appropriate to treat with DCA [39].
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Figure 6. Sodium dichloroacetate molecular structure

2.2.2.4

Solvents

Some agents to be tested have low solubilities in aqueous media, and it may be
necessary to use an organic solvent to dissolve them. Ethanol, propylene glycol, and
dimethyl sulfoxide have been used for this purpose, but may themselves be toxic to
cells. Hence the minimum concentration of solvent should be used to obtain a solution.
The agent may be made up at a high concentration in, for example, 100% ethanol, then
diluted gradually with balanced saline solution (BSS) and finally diluted into medium.
The final concentration of solvent should be <0.5% and a solvent control must be
included (i.e., a control with the same final concentration of solvent but without the
agent being tested). Care should be taken when using organic solvents with plastics or
rubber. It is better to use glass with undiluted solvents and to use plastic only when the
solvent concentration is <10%.

2.3

High Throughput Screening (HTS) on Drug Discovery Process
Current drug discovery relies on massive screening of chemical libraries against

various extracellular and intracellular molecular targets to find novel chemotypes with
the desired mode of action. In recent years, high-throughput technologies for
combinatorial and multi-parallel chemical synthesis, automation technologies for the
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isolation of natural products, and also availability of large compound collections from
commercial sources, have substantially increased the size and diversity of compound
collections among most pharmaceutical companies, in some cases exceeding one
million distinct chemical entities [14].
The strong increase in both the number of available compounds as well as
molecular targets has caused a need for new technological devices able to manage this
increase. Various technologies for assay miniaturization, lab automation and robotics
have been developed to enable testing of chemical compounds in biological systems
High Throughput Screening (HTS) can test 10,000–100,000 per day, and ultra-High
Throughput Screening (uHTS) in excess of 100,000 per day [14].
A recent study conducted utilizing gold nanoparticle arrays and chemically
detecting cancer biomarker interleukin-6 (IL-6) in serum [40], provided the following
detection limits, sensitivity and linear dynamic range for clinical settings[numbers]. This
study demonstrated…
Moreover, immunochemical sensing device have been demonstrated useful for
pathogen detection in a paper fluidic and inkjet dispensing based approach [41].
Previous work has been done to study inkjet technology as high throughput technology
in a bacteria-antibiotic model [42] and enzyme-substrate/inhibitor model[43]. Even
though, it has been demonstrated that the inkjet technology is a promising tool for future
drug screening at low cost, future evaluation test can be done using different
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biomaterials. More targets can be identified for future development of this methodology
under the drug screening field.

2.4

Biological Microarray Technologies
Extrusion based robotic systems remain the standard technology used for the

liquid handling portion within the high-throughput screening process. Main drawbacks of
the current screening process are that they
•

Remain time consuming and costly,

•

Incur in substantial waste of expensive compounds, plates, disposable
tips, and diluents,

•

Require high level of expertise,

•

Are limited by well-plate footprint, and

•

Are prone to cross-contamination

In order to solve these challenges, different approaches have been investigated; many
of those improved throughput, lowered test volumes, and increased the density of test
wells. A comprehensive review of these technologies, which are classified as contact
and non-contact, based on the fluid dispensing mechanism is published elsewhere[7].
Figures 7 and 8 summarize the various technologies and Table 2 discusses advantages
and disadvantages of each of those technologies.
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Figure 7. Contact-based technologies for high throughput array construction[7].
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Figure 8. Non-contact based technologies for high throughput array construction[7].

21

Table 2. Comparison of high throughput assembling techniques[7].
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Among all technologies reviewed, inkjet bioprinting is most promising due to its
non-contact capabilities, which can avoid sample cross-contamination, the expandability
of cartridges, high throughput, high precision (around 10-50 um), and small volume of
reagents dispensed.

2.5

Inkjet Bioprinting
Recently, the inkjet printing technique has attracted much attention as a useful

tool for the fabrication of cellular patterns on substrates. In this technique, precise target
positions on a substrate can be assigned by computer-assisted deposition. Inexpensive
commercially available printers can be used in these experiments with little modification.
Several studies have shown the successful creation of cellular patterns mainly on
hydrogel substrates by using this inkjet printing technique [44-49]. There are two main
strategies, printing with living cells and printing with cell adhesion molecules [50].
Boland and coworkers reported that Chinese hamster ovary cells and primary
embryonic hippocampal or cortical cells can be directly printed onto a substrate with a
desire pattern without loss of cell function [51, 52]. The printing of cell adhesion
molecules such as collagen or cell growth/differentiation factors such as FGF-2 and
CNTF with a desired pattern onto a substrate has also been demonstrated using inkjet
printers [43, 47-49].
Thermal printers operate by heating of a small air bubble that ejects a drop of ink
from the nozzle as it expands. Figure 9 shows a schematic of inkjet bioprinting along
zoomed images of micrometer-size nozzles.
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A typical heating pulse lasts a few

microseconds and drops are fired at a rate of about 5 kHz. For the author, home built
systems based on HP head have proven an excellent combination of robustness and
cost effectiveness. However, they offer only a narrow window of nozzle voltages and
fluid properties in which jetting can be achieved. Therefore ink formulations must fall
within a relatively narrow range of viscosities and surface tensions. In addition they
have limited tolerance to solvents and strong acids. Customizing cartridges of thermal
printers for biological inks is currently being investigated by manufacturers like HP and
Olivetti, thus in the future one may be able to use more viscous fluids and avoid the
relative large amount of ‘dead volume’ that is found in current head designs.
Thermal print heads can be mass-produced and are therefore inexpensive and
disposable. Most piezoelectric print heads can be cleaned ultrasonically but irreversible
damage is still common. Existing thermal inkjet heads are not very solvent resistant
and have a limited resistance to acids and bases but bioprinting solutions are mostly
aqueous and neutral.

While piezoelectric inkjet heads can be solvent and acid

resistant, many commercial heads run at high voltages and can be vulnerable to slow
degradation in water. In general, thermal inkjet are much more robust than piezoelectric
heads in terms of the range of inks that can be printed. The ranges of viscosities and
surface tensions of fluids that can be printed are up to 20 cP and 30-40 mN/m
respectively. Thermal droplet ejection is a rugged process that is relatively insensitive to
other ink properties, as long as some component of the ink can be vaporized.
Rheological properties are less important to determine drop formation and jettability,
than for piezo-based print heads. Thus even high molecular weight polymers at higher
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concentrations may be jettable. There may still be some limitation for biopolymers due
to re-filling the ink chamber in the appropriate time to allow for subsequent nozzle
firings.
There are several disadvantages of inkjet printing systems over other microfluidic
systems; for instance, its resolution of 15-50 µm is lower than other photolithographic
and microfluidic techniques. Moreover, this technique is restricted to low viscosity fluids
and low cell density to avoid clogging issues [47]. In addition, control of dispensed
particles is lost once the liquid has left the confinement of the nozzle, and issues related
to drying and spreading of the ink on the surface may render the process less useful. A
recent study, however, showed that micropatterned protein spots remained stable on a
PEG surface even after extensive washing, demonstrating that the wetting issue can be
solved [53]. Further research into ink rheology and fixations properties of bio-inks is
needed to lead improvements in resolution, densities, and to minimize clogging issues.
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Figure 9. Inkjet technology mechanism. A) Actual inkjet printer cartridge and zoomed image of nozzle
actuated to dispensed ink B) Actual picture of cartridge nozzles in research, approximately 50μm in diameter
C) Illustration of heater element on side of every nozzle dispensing mammalian cell.
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CHAPTER 3: PROJECT RATIONALE
This study is an endeavor to develop a systematic cellomic anticancer drug
screening platform based on inkjet printing technology, which will evaluate several
anticancer drugs on cancerous and non-cancerous cell lines to identify which treatment
and what dosage will be safer and more effective. In particular, a cancerous cell line,
HepG2, and a healthy cell line, prostate human epithelial cells (PHEC), have been
evaluated under the cytotoxic effect of two chemotherapeutic drugs, cyclophosphamide
monohydrate (cytoxan) and dichloroacetate acid (DCA). The screening process is
duplicated under the standard micropipetting protocol to ensure that outcomes from the
application of inkjet technology fully mimic traditional screening outcomes. Half maximal
and 90 percent inhibitory concentrations (IC50, IC90) are obtained from the doseresponse curves to correlate both technologies.
The screening platform developed will increase the amount of data obtained from
a given sample. The patient’s samples -including biopsied cells, saliva, blood, urine, and
so on- can be screened at low volume rates along with more targets, thus resulting in
less sample usage and more valuable information for an accurate disease diagnosis in
the field of medical, environmental, and food analysis. The platform described in this
manuscript suggests a change of strategy toward creating a higher density array
removing the walls-restricted well-plate approach and minimization of volumes used for
an anticancer drug screening.
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3.1

Hypothesis

Small quantities of cancer and normal cells can be deposited with and inkjet
printer and behave similar to larger, pipetted amounts of cells in terms of growth
Small quantities of two chemotherapy drugs can be precisely added with help of
an inkjet printer to standard cell culture plates without losing potency.

3.2

Objectives

a) Standardized miniature platform. Determine minimum dispensable drug volume and
associated minimum cell numbers. Determine maximum array density capabilities
and fabrication throughput.
b) Verify screening effectiveness with two model drugs and compare against
conventional drug screening platform (micro-pipetting). Determine appropriate cell
seeding, drug concentrations, survival rates. Develop protocol to minimize time
required to obtain outcome results and maximize reutilization of drugs.
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CHAPTER 4: HIGH THROUGHPUT MINIATURE DRUG SCREENING
PLATFORM USING BIOPRINTING TECHNOLOGY
4.1

Abstract
In the pharmaceutical industry, new drugs are tested to find appropriate

compounds for therapeutic purposes for contemporary diseases. Unfortunately, novel
developed compounds emerges at expensive prices and current target evaluation
processes have limited throughput, increasing cost and time for drug development. The
present work shows the development of the novel inkjet-based deposition method for
assembling a miniature drug screening platform, which can realistically and
inexpensively evaluate biochemical reactions in a picoliter-scale volume at highthroughput rates. Applying a modified Hewlett Packard (HP) model 5360 compact disc
(CD) printer, green fluorescent protein (GFP) expressing Escherichia coli cells along
with alginate gel solution have been arrayed on a coverslip chip under a repeatable
volume of 180 ± 26% picoliters per droplet; subsequently, different antibiotics droplets
were patterned on top of them, in such a manner that inhibition of bacteria growth was
evaluated. The proposed platform was compared to current screening process
validating its effectiveness. The viability and basic function of the printed cells were
evaluated, resulting in cell viability above 98% and insignificant or no DNA damage on
human kidney cells transfected. Based on the reduction of investment and compound
volume used by this platform, this technique has potential to improve the actual drug
discovery process at its target evaluation stage.
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4.2

Introduction
Drug discovery is a time-consuming process and a costly endeavor that requires

substantial investment in financial and human resources. It is estimated that more than
800 million dollars over 12-15 years are invested for the development of a single
approved new drug [54]. A large portion of the investment is associated with the fact
that the new compounds are hard to obtain, particularly in the early stage of
development, which drives to expensive research and limited material availability. A
cost saving opportunity is foreseeable in the capital invested in fabrication tools for
current drug screening platforms. In some cases, a low-cost fabrication tool is of primary
consideration, in particular for low resource settings areas. Therefore, low-cost tools
and methodologies have to emerge for these underrepresented situations.
Moreover, significant increase in the number of chemical compounds for testing
and molecular targets for leading findings can be accommodated only via substantial
miniaturization of high-throughput screening (HTS) assays. Applications are driven by
the desire to miniaturize processes in order to effectively combine compounds and
targets in a rapid manner. In the HTS platforms, higher density at lower volume rate
assay plates are pursued to decreased reagents usage and increased throughput.
However, most of the existing methods apply a micro- or nano-scale of drug volume at
relatively low throughput. In general, the throughput of the current screening processes
is limited to 200,000 assays per day at a volume rate of 2.5-100 μl per well [14], which
partially satisfies the increasing need of massive screening for future drug development.
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To overcome these shortcomings, there is a clear need to develop new technologies to
fabricate the next generation of drug screening platform at higher throughput.
Inkjet printing technology offers a possible solution to these issues. This
technology is based on the rapid creation and release of liquid droplets, followed by
their precise deposition on a substrate. Current commercial inkjet printer generations
have reached droplet volumes in the range of 1-95 picoliters (pl), patterning speeds
over 250,000 droplets per second [45], and a low-end price in the range of hundreds of
USD (United States Dollars). These practical and efficient characteristics to arrayed
biomaterials and living organisms [44, 45, 55-57] make this technique suitable for high
throughput screening applications. Vast number of studies have used to construct
microarrays of biomaterials via extrusion systems [58], laser printing [59-61], direct
writing [62-64], thermal and piezoelectric inkjet systems [43, 46, 47, 65-67], microfluidics
[68, 69], and other emerging technologies [70-72].
However, to date, only few efforts have been conducted to demonstrate the
usage of inkjet technology for drug screening at low volume rates (picoliters range).
Such is the case of Arrabito et al. [43] where utilizing a single nozzle piezo-electric
printer (Dimatix Materials Printer from Fujifilm, model DMP-2800) biological screening
capabilities were demonstrated in a enzymatic inhibitor model. Microarray constructed
was proposed to satisfy the requirements of rapid, low-cost, miniaturized (1–10 pL), and
HTS (10 spots/s) by easily spotting entire chemical libraries onto solid-supported
biological targets. However, incorporation of living organisms (i.e. breast cancer cells, e.
coli) is key for drug screening.
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For efficient and accurate drug screening purposes, the amount/number of
targets (living organisms) should match the dosage of the drug to be tested. Therefore,
the HTS system should account for simultaneous deposition of living organisms and
drugs in a small volumetric fashion and as post-processing, screening of the cell
physiological characteristics under drugs presence will be required. Unfortunately the
existing drug screening platforms lack such mechanism and capability. A drug
screening platform has been built employing a modified off-the-shelf office inkjet printer
that can simultaneously deliver small volumetric amounts of given biochemical
substances and corresponding living organism targets to meet the aforementioned
needs. This platform can effectively evaluate the behavior of the living organisms in the
presence of different drugs (drug screening). In this study we have analyzed the viability
and function of the printed bacterial cells by the bacterial live/deadTM assay and plasmid
gene transfection experiment. To evaluate its drug screening capabilities, bacteria along
with different typical antibiotics were patterned in such a manner that we assessed the
bacteria proliferation under three different antibiotics present. Results were compared
with manually micro-pipetted samples (most popular method use) containing the same
bacteria and antibiotics in order to validate the accuracy of data obtained by the inkjet
technology.
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4.3

Materials and Methods

4.3.1 Bacterial Strain and Suspension
Escherichia coli (E. coli) Efficiency™ DH5α cells (Invitrogen, Stockholm,
Sweden) were grown overnight at 37ºC on a Trypticase™ Soy Agar plate (Becton
Dickinson & Co, Cockeysville, MD). The bacterial print suspension was prepared
according to the protocol we published previously [56]. Briefly, two loopfuls of organisms
(representing approximately two large colonies) were transferred into a centrifuge tube
containing 5 ml sterilized water. This formed the original print suspension of bacteria.
The cell concentration in the E. coli solution was determined by the standard plate count
method [73]. The tubes containing bacterial suspensions were forcefully shaken before
printing, to break up clumps and ensure good distribution of the bacteria. The
movement of the cartridge during printing allowed the cells to be maintained in
suspension.

4.3.2 Agar Films Preparation
Print substrates were made from soy agar. 7ml of prewarm sterilized BBL™
Trypticase™ Soy Agar solution (Becton Dickinson & Co, Cockeysville, MD) were poured
into 100 mm Petri dishes, containing three 24x40mm precleaned sterilized premium
cover glasses (Fisher Scientific, Pittsburgh, PA) The solution was allowed to cool at
room temperature; when cooled, a thin gel layer was formed on the substrates with a
calculated layer thickness of about 1 ± 0.12 mm. This substrate provides the sufficient
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nutrients for bacterial proliferation. Agar films were used to evaluate viability of bacteria
only.

4.3.3 Viability Evaluation of the Bacterial Array
The viability of the Efficiency™ DH5α cells contained in the printed agar films
were evaluated by a two-color fluorescence bacterial live/dead assay (Live/dead®
BacLight bacterial viability kit, Invitrogen) using a solution consisting of 3.34 mM
SYTO 9 in anhydrous Dimethyl sulfoxide (DMSO) 4.67 mM hexidium iodide in
anhydrous DMSO (Invitrogen). The samples were viewed using a fluorescent
microscope, and the viability of the cells was evaluated by counting the number of cells
stained with SYTO 9 (green), and this number was compared to the total number of
cells. The viability results of the printed samples were compared to control samples, in
which Efficiency™ DH5α cells were manually plated onto a standard tissue culture plate
(BD Biosciences, San Jose, CA).

4.3.4 Cell Functionality
The thermal inkjet printing process involves a series of physical interventions
including heating (up to 200-300 °C) and mechanical stress (up to 10 ms-1) [47]. To
verify if these inkjetting physical interventions could affect the basic properties and
functions of the bacterial cells, we examined certain plasmid genes of the printed cells
and tested their transfection abilities with mammalian cell line. The pEGFP contained
host E. coli strain library Efficiency™ DH5α (Fisher Scientific, Pittsburgh, PA) was used
for plasmid production. The pEGFP-C1 plasmid was produced and purified in small34

scale using QIAGEN plasmid mini kit (Qiagen Ltd., Hilden, Germany) according to
company plasmid purification handbook, 2005. Then it was transfected with human
kidney cell line 293 (American Type Culture Collection CRL 1573) using FuGENE® HD
Transfection Reagent (Roche, Basel, Switzerland). The culture of human kidney 293
cells was performed according to the vendor’s protocol.
Controls were defined as negative when no plasmid was used for human kidney
293 cells transfection, and as positive control when cells were transfected with pEGFPC1. Two sample groups were evaluated; the first was the plasmid collected from
bacteria dispensed by the inkjet printing process and the second was the plasmid
collected from bacteria dispensed manually by micropipettes.

4.3.5 High Throughput
An array of points was designed using PowerPoint software (Microsoft Inc.,
Redmond, WA), formatted under the smallest font size allowed by the software (font
size 1), and time was measured from the start of delivery of bacterial cells or drugs until
completion of printing. Results were recorded in dots per seconds and the diameter size
of the dispensed points was recorded. Typically 41 dots about 420-μm-spaced were
dispensed in sequential lines.
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4.3.7 Volume Determination
To determine the amount of volume being dispensed by the inkjet printer, an
evaluation test was designed to enable theoretical data of volume delivered. Sodium
chloride (Acros Organics, Geel, Belgium) and calcium chloride (Acros Organics, Geel,
Belgium) were dissolved in distilled water (Millipore, Billerica, MA) in the closest ratio to
full saturation, 1:3 and 1:6 respectively. Both solutions were printed with black and color
cartridges; and volume was determined by protocol described below.
The procedure for determining the dispensing volume was as follows: a) Clean
glass slides were weighed with an analytical balance (model ALF-204, Fisher Scientific,
Pittsburgh, PA), b) Different patterns were printed utilizing both solutions (as previously
stated) onto clean glass slides to correlate the dot size with the volume dispensed, c)
Glass slides with solutions were exposed to 100 ± 15 °C in an oven (Isotemp, Fisher
Scientific, Pittsburgh, PA) for at least 10 minutes to allow all the water to evaporate, d)
The glass slides, with the remaining salts, were weighed with the analytical balance, e)
The printed solution concentration and dot sizes were utilized to determine each volume
per dot (Volume (nl) = mass(g) / concentration (g/nl)). However, since the balance had
limited precision, arrays and a number of dots were set up in such a manner that a
significant difference between the clear and salt-containing glass slides was obtained.
As control, a controlled volume (100 µl) was dispensed over a glass slide under a
conventional micropipette deposition method. Percentile errors were obtained from the
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test to quantify the tolerance error of the printed parameters under both substances
being subjected to the test. Data was recorded and presented in the results section.

4.3.8 Smallest Replicable Volume Dispensed of E. coli
Microsoft PowerPoint software was used to edit a colony array pattern. Three
dots in sequential lines under different font sizes (16, 8, 3, 2, and 1) were printed. A
black cartridge was emptied of its contents, thoroughly washed, rinsed with a 70%
ethanol solution and distilled water, and dried in a sterilized Labculture® Class II, Type
A2 Biological Safety Cabinet (ESCO, Hatboro, PA). This cartridge was filled with 1 ml of
bacterial suspension (E. coli suspended in broth agar) to print a designed pattern. E.
coli concentration was measured using BioPhotometer plus absorbance reader
(Eppendorf, Hamburg, Germany) and the volume calculated from the formula derived in
the volume determination section. The E. coli suspension was ejected onto an agar
coated coverslip and bacterial deposition was read under fluorescent microscope for
each dot. Results for cell numbers were plotted, determining the smallest replicable
volume being dispensed by the inkjet printing technology.

4.3.9 Drug Screening
To build a single capsule drug screening test and avoid migration by diffusion of
the antibiotics and bacteria towards the rest of the deposited dots, three consecutive
layers (Figure 10) were printed to encapsulate droplet assays. Over a glass slide, the
first printed layer consisted of a solution of sterilized Broth BBL™ Trypticase™ Soy
Agar. The second layer consisted of a 0.3% alginic acid solution (Acros Organics, Geel,
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Belgium), a liquid known to cross-link under mild conditions to form a biodegradable
hydrogel scaffold [74]. Finally, the third layer consisted of an alternating solution of three
different antibiotics mixed in a 1:1 ratio to 1.4% Calcium Chloride (CaCl 2 ); all three
layers were printed. CaCl 2 is known to promote the cross-linking of the individual
alginate chains resulting in an encapsulated environment. Black and color cartridges
were used as appropiate to take advantage of the four compartments provided by the
system employed. The first cartridge (usually containing black ink in 1 compartment)
was used to print bacterial suspension, while the second cartridge (usually containing
magenta, cyan, and yellow ink in three separated compartments) was used to print
three different chosen antibiotics mixed with calcium chloride (1.4% in H 2 O). Chosen
antiobiotics were penicillin/streptomycin (Fisher scientific), antimycotic (15240-096,
Invitrogen), and kanamycin sulfate (15160-054, Invitrogen).

Control samples were

printed under no antibiotic presence to asses cell population per dot.
Along with the printed samples, micropipeted dots were arrayed on other glass
slides, mimicking the drug screening platform proposed at regular volume rates
(microliter scale). Results of both proceses were normalized to enable a comparison
frame. Normalization was based on the cell population on dots without antibiotics (100
% of the cell population at their distinct volumes), limiting cell population on dots with
antibiotics. Results were recorded and plotted. This procedure validates the proposed
new inkjet drug screening method.
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Figure 10. Miniature screening platform. (A) Schematic illustration of the bioprinting process for
encapsulating drug-screening droplets on glass slides. (B) Left: representative image of the three layers
build of the screening spot. Black scale 500 μm. Right: representative fluorescent image of the screening
spot[1].

4.3.10

Image Processing

The technique of selection of similar features on digitized images has previously
been employed in previous bioengineering research projects [75-77]. Tone adjustments
were made to the original images using the Hue /Saturation tool. The saturation and/or
hue of a selected color (using the Eyedropper tools) were modified to i.e. render
fluorescent green (live cells) into a more bright green color which separates well from
the green background chromogen. Selection of specific color (either fluorescent green
or red) in digitized images was used to quantify by means of histogram information
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(color pixel numbers, total selected pixel) the amount of living and death cells. This
method has been utilized for the quantification of bacteria in the cell viability,
functionality, smallest replicable volume dispensed, and drug screening tests.

4.4

Results

4.4.1 Cell Viability
The survival rate of the printed Efficiency™ DH5α cells within the particles was
analyzed by a commercial cell survival assay and compared to the controls (n=3), which
were prepared by manually placing the cells onto a standard Trypticase™ Soy Agar
plate. Printing spots were patterned at three distinct volume sizes: 60, 35 and 7
nanoliters, while control samples were limited to 5 microliters. Percentage of live cells
resulted from the test were 99.57 ± 0.108%, 98.81 ± 0.238%, 98.79 ± 0.278%, and
99.66 ± 0.173% respectively. The live/dead assay demonstrated that more than 98% of
printed cells remained viable within the microparticles (dots) assessed. After this
reading, bacteria was stored in an oven at 37ºC, resulting in exponential proliferation
reaching the point that colonies were distinguished by the naked eye.

4.4.2 Cell Functionality
After the transfection test was performed, it was found that animal cells expressed GFP
plasmids collected from both sample groups (printed E. coli and control sample
(micropipetted). Figure 11a and b shows a representative imaging of human kidney 293
cells transfected with the pEGFP plasmids obtained from both groups. The fluorescent
expression was evaluated by the image processing method described previously.
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Figure 1c shows the percentage of pEGFP expressed in human kidney 293 cells
collected from both groups. It was found that both sample groups were significantly
equal (p>0.05).

Figure 11. Representative images of human kidney 293 cells transfected with the pEGFP plasmids obtained
from the printed bacterial cells (A) and the control (B), a manual micro-pipetted seeding of cells. Percentage
of pEGFP expressed on cells collected from manual and print dispensed samples (C). Samples are
significantly equal (p > 0.05) (n = 3). Scale bars for A and B are 500 μm[1].

4.4.3 High Throughput
This technology has been recorded as a rapid process, which allows for the
printing of spots 150–240 µm in diameter at a rate of 213 assays per second, having a
theoretical capability of running more than 18 million targets per day.
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4.4.4 Volume Determination
Sodium chloride (NaCl) solution was found to be the most reliable substance to
be used as a control for the volume determination test, as its percentile error remained
below 5 percentile points (4.30 ± 1.66%). On the other hand, calcium chloride (CaCl 2 )
reaches an error of 10.63 ± 1.39%. Therefore, the sodium chloride solution was
selected to determine the printing volume in relation to its printing area. Following the
procedure explained in the method section, actual data containing the area of the
abscissa (x-axis) and the volume of the ordinate (y-axis) was plotted. The actual volume
data for deriving this equation was in the range of thousands of picoliters (nanoliters).
Different trend lines were drawn, finding a positive correlation within the two sets of data
(correlation = 0.99915), which confirms the direct relation between the area and the
volume of the printed dots. The polynomial trend line was found to be the best line fit
(regression line) (R-squared = 1.0), which resulted in a polynomial equation that
describes the behavior of the volume with respect to the printed area. The resulted
equation was:
𝑣𝑜𝑙𝑢𝑚𝑒 (𝑦) = 3.0789 𝑎𝑟𝑒𝑎(𝑥)3 − 20.746 𝑎𝑟𝑒𝑎(𝑥)2 + 7643.5 𝑎𝑟𝑒𝑎(𝑥) + 3 𝑥 10−7

This equation was utilized to calculate volume for the bacterial printing sections based
on the smaller areas (diameters) of printed dots.

4.4.5 Smallest Reliable Volume Dispensed of E. coli
It is desirable that in every assay the amount of bacteria cells delivered in each
dot remain as constant as possible. Figure 12b shows the results of various numbers of
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E. coli cells at different font sizes. It was found that the smallest reliable volume was
under font size number 3, which dispensed 180 ± 26% picoliters per each colony dot,
containing an average cell number of

1,116.7 ± 34.3% (n=3, standard deviation)

bacteria cells. Even though the dots exhibited satellite printing spots (Figure 12a), the
dispensing area remained fairly controlled. A bacteria spread distribution is visualized in
Figure 12c.

Figure 12. Smallest replicable dots. (A) Array of dots, point size number 3. (B) Number of E. coli strain library
TM

Efficiency

DH5α cells at different font sizes (n = 3). (C) Representative image of smallest replicable dot.

Scale bars: 500 μm (A) and 50 μm (C)[1].

4.4.6 Drug Screening
Three bacterial inhibitors were evaluated under the proposed miniature drug
screening. Antibiotics included in the test were a penicillin/streptomycin mixture,
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antimycotic, and kanamycin sulfate. Figure 13 shows the behavior of the printed
microparticles (n=6) comparing E. coli under these different antibiotics and under no
antibiotics presence as a control. Within the following 10 minutes after printing, the
viability test was performed, revealing that the three antibiotics restricted the viability of
the cells below the 50% of the control samples (no antibiotic presence). Moreover, to
validate if this new method is as effective and efficient as an antibiotic screening method
at a low volumetric constraint, it was compared to the manual micro-pipetting
methodology. Figure 14 illustrates the normalized plotted data, comparing the E. coli
expression under different circumstances of both methods. Direct correlation was
observed at both methods, demonstrating that the bioprinting method at a low volume
setting has similar results to standard micropipetting approach.

Figure 13. Drug screening of the printed microparticles (n = 6), comparing E. coli under different antibiotics
and under no antibiotics presence as a control (data is shown in cell numbers +/− standard deviation)[1].
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Figure 14. Normalized graph comparing behavior of E. coli under different antibiotics presence by inkjet
printed and manually dispensed samples (n = 3)[1].

4.5

Discussion
Drug discovery process has many areas of improvement. While the costly and

time-consuming concerns are mostly associated with the pre-clinical and clinical trials
there is crucial need on continue on the development of drug titration technologies. The
miniature drug screening platform herein described has been developed in an effort to
alleviate the money and time investment on these endeavors. The major scientific value
of this research stands on the demonstration of the inkjet printing technology benefits to
downsizing the volume usage of valuable biochemical substances for drug screening
applications at a minimized investment. This advantage clearly fits the mission of
pharmaceutical firms. Moreover, developing countries can take advantage of this
accessible technology to investigate diseases that are of their particular attention. For
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instance, tropical diseases are still common in these countries, the implementation of
this platform increases the availability for investigation of such diseases
In this study, living organisms and antibiotics were patterned by inkjet printing
technology. The non-contact characteristic of the inkjet technology provides an
advantage to maintaining the isolated droplets that were tested. Furthermore, the
viability assay verified that this method does not significantly affect the number of viable
cells, which supports the hypothesis that this method can be used to effectively deliver
living organisms [44]. Moreover, genetic material (GFP plasmid) in the bacteria was not
significantly affected by the printing process.
Regarding high throughput, the potential 18 million assays per day denote a well
above solution for the current screening limitations [14]. This result locates the inkjet
technology above the ultra-high throughput, which corroborates its candidacy to solve
the bottleneck associated to the target evaluation within the drug discovery process
[78].
In the determination of the volume being dispensed by the inkjet technology,
sodium chloride (NaCl) solution was found to be the most accurate substance to be
used over the calcium chloride (CaCl 2 ), which can be explained by the fact that the
second solution can create strongest bonds with water molecules. However, on top of
the error on the measurement method (determined as <5%) concerns exist about the
different mechanical properties of the printed bioinks to construct the drug screening
platform. This concern is alleviate by the fact that viscosity and surface tension (no data
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reported) of all bioinks used in these experiments are not significantly different than the
saline solution used to determining the dispensing volume system. Further concerns
exist on the exposure of bioinks to heat, in the sense that bioink compositions can be
modified during the printing process. Future studies are expected to occur to further
understand and solve this type of concerns.
The capability of dispensing 180 ± 26% picoliters per colony dot represents the
main advantage of this platform. This work demonstrates that a modified commercial
office inkjet printer can deliver living organisms and substances under a small
volumetric constrains for drug screening purposes in a chip (plane) design basis. Earlier
discovered drugs are launched to the market in expensive presentations to recover their
discovery process investment. The miniaturization of the platform herein demonstrated
show potential to reduce the resources expenditure in the drug screening processes. To
exemplified this resource reduction we can consider that any given chemical used in the
screening platform cost 200 USD per μl, while current extrusion robotic systems usually
dispense volumes in the range of 0.1-2 μl for each dot assay the 133-226 pl, prove
feasible in this manuscript, will reduced the cost per dot assay from 20-400 to 0.0260.045 USD. On top of that, commercial office inkjet printers (HP, canon, epson) have
reach sale values below the 100 USD which overpasses the investment in the range of
10,000-100,000 USD of more sophisticate equipment.
More importantly, in regards to the drug screening results, it can be seen in Fig. 5
that normalized data demonstrates the similarity of both methods along the test sample
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groups. This confirms that the inkjet printing technique is an effective method to
minimize the typical drug screening test. In particular, the similar composition found in
the penicillin/streptomycin mixture and the antimycotic justified the similarity in inhibition
results, where even overlapping variance occurs. On the other side, kanamycin sulfate
inhibition results between methods differ, suggesting that kanamycin sulfate
effectiveness becomes compromised by the implicit heat existed during the inkjet
printing process.

4.6

Conclusion
In this research project, it has been demonstrated that this method can effectively

deliver replicable cell volume at level of hundreds of picoliters. Due to the reduction of
volume, this method will increase the effectiveness of the resources utilized for
emerging drug screening processes. Moreover, it was proven that bacteria maintained
viability and function after the printing process. Furthermore, different antibiotics can be
screened at an ultra-high throughput. The results show promising usage of resources
for future ultra-high throughput drug screening through new biochemicals under usage
of accessible equipment. The present drug screening method represents a low cost
possible solution to stimulate the drug discovering process for developing countries.
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CHAPTER 5: COMPARISON OF IC50 AND IC90 BETWEEN
MICROPIPETTED AND INKJET PRINTED CHEMOTHERAPY DRUGS
ON CELL GROWTH INHIBITION
5.1

Abstract

The new paradigm of personalized medicine is beginning to affect clinical practice. In
particular, many of the advances in genomics and proteomics have made personalized
screening and therapeutic inventions possible. On chip, cellomics approaches to
screening and intervention are becoming more commonplace. Cancer therapies may
benefit from the rise in ‘-omics’ technologies. In addition, the availability of rapid
screening data is crucial to mitigate cancer propagation and increase the possibility of
patient recovery. This study is an endeavor to develop a cellomic anticancer drug
screening process based on inkjet printing. Previous research has demonstrated that
inkjet based screening can reliably create isolated spots arrays at low volume (180 pl)
and high throughput (213 spots/sec). Herein we study whether inkjet printing small
volumes of anticancer drugs along with few cells has merit as a tool to fabricate cellomic
chips. Cells, from the hepatocellular carcinoma line HepG2 and the epithelial cell line
PHEC, were printed with an inkjet device and thus arrayed on a 96-well plate for culture.
The inkjet device was described before [1]. At mean exponential proliferation rate,
cyclophosphamide monohydrate (Cytoxan) and dichloroacetate sodium (DCA) at
standard chemotherapeutic concentrations in the range of 0-50 mM were printed at
continuously increasing densities in order to expose cultures to a drug concentration
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gradient. Anticancer drugs were studied under two solvents by means of dimethyl
sulfoxide and PBS. The printed volumes were in the nanoliter range accounting for 625
± 20% cells per spot. MTS assay was utilized to determine the amount of viable cells
upon 24 hours of drug exposure followed by 48 hours for cell recovery. Half maximal
and 90 percent inhibitory concentrations (IC50, IC90) were obtained from the doseresponse curve. Along with the proposed cellomic chip, a screening platform using
traditional micropipetting technique was built to compare results and validate inkjet
based screening platform applicability.
Results obtained show that both cell lines were growth inhibited under both drug
regimens.

The IC50 values obtained by micropipetting and inkjet based screening

varied less than 1mM suggesting that the proposed screening platform closely mimics
the traditional screening outcome. However the IC90 values obtained vary in the range
of 1 to 4.5 mM. The resulted IC50 indicates that 9.35 and 4.3 mM will be sufficient to
inhibit growth of both cell lines under cytoxan and DCA treatment, respectively. In
comparison to literature, IC50 results vary based on the cell lines used for the screening
platform, but are generally in the range of 4-10 mM. Thus our results are consistent
with those that used much larger volumes, validating our hypothesis that screening
assays can be further miniaturized.
Inkjet technology shows promise to be used to determine dosages and treatment
modalities using the patient’s limited supply of biopsied cells. Future expansion of the
screening process to more drugs and usage of actual patients’ biopsied cancer cells will
result in valuable data to forecast efficiency of potential drug therapies.
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5.2

Introduction
The new paradigm of personalized medicine is beginning to affect clinical

practice. In particular, many of the advances in genomics and proteomics have made
personalized screening and therapeutic inventions possible. On chip, cellomics
approaches to screening and intervention are becoming more commonplace. Cancer
therapies may benefit from the rise in ‘-omics’ technologies. In addition, the availability
of rapid screening data is crucial to mitigate cancer propagation and increase the
possibility of patient recovery. This study is an endeavor to develop a cellomic
anticancer drug screening process based on inkjet printing. Previous research has
demonstrated that inkjet based screening can reliably create isolated spots arrays at
low volume (180 pl) and high throughput (213 spots/sec)[1]. Herein we study whether
inkjet printing small volumes of anticancer drugs along with few cells has merit as a tool
to fabricate cellomic chips.

5.3

Materials and Methods

5.3.1 Cell Lines and Culture Conditions
Human hepatocellular carcinoma (HepG2) and prostate human epithelial (PHEC)
cell lines were a gift from Dr. Zhang (Biology Faculty Professor at the University of
Texas at El Paso). Both cell lines were cultured with Dulbecco’s Modified Eagle’s
medium (DMEM; Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin in a humidified atmosphere in 5% CO 2 at
37°C. HepG2 was defined as positive control cell line, which was expected to be growth
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inhibit during the screening process; whereas epithelial cell line was proposed as
negative control. Due to the increasing need for search of new compounds with
cytotoxic activity against cancer cells and mitigated or zero cytotoxicity to the normal
cells. Normal cell lines associated with cancer cell lines screened have to be evaluated
as well to minimize secondary effects on cancer treatment. Epithelial tissue lines and
covers organs and the whole body, among the four main tissue types existing on the
body (muscle, connective, nervous, and epithelial tissue), the epithelial cells (EpC) are
the most abundant. This abundance makes EpC more susceptible to be affected by
cancer growth and its anticancer treatments. EpC were chosen as the expected
negative cell line control to evaluate the expected side effects of any given anticancer
drug regimen

5.3.2 Printing Suspensions and Printing Systems
Cyclophosphamide monohydrate (AC20396,Fisher scientific) and dichloroacetate
acid (DCA) in the form of sodium dichloroacetate (AC33828, Fisher scientific) were
dissolved in dimethyl sulfoxide (DMSO) and phosphate-buffer saline (PBS) to a stock
concentration of 10 mg per each ml, further dilution was made by adding 10ml of EMEM
prior to addition to cell lines. A wide range of concentrations in log increments (e.g., 1
μM–1 mM, and control) were used for first attempt and a narrower range (log or linear)
was used based on the results from the first range, for subsequent attempts.
One hundred µl of stock solutions were used to fill a sterilized cartridge (CL-241,
Canon). Drug solutions were printed simultaneously using a modified thermal inkjet
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printing system (MG2120, Canon). Printer modifications include the override of paperfeeding sensors and removal of printing feeding mechanisms to allow printing over 96well plates.

5.3.3 Drug Screening Protocol
Cell survival on presence of therapeutic drugs was evaluated via standard
microtitration MTS cytotoxic assay [79]. Different 96-well plates were used to compare
the conventional method, micro-pipetting, against the inkjet printing method. Assays
were triplicated per drug concentration and control sample group. Drug concentrations
were prepared up to 10 folds between 5 and 50 mM. Drug exposure was maintained for
24 hours. Half maximal and 90 percent inhibitory concentrations were obtained from
dose-response curves. Control samples were defined as follows: positive control: stock
drug concentration, and negative control: pure DMSO and PBS, diluted in EMEM for a
final concentration below 1%.
Cells in the exponential phase of growth were exposed to the cytotoxic drug.
After 24 h exposure, the drugs were removed and the cells are allowed to proliferate for
two to three population-doubling times (PDTs) in order to distinguish between cells that
remain viable and are capable of proliferation and those that remain viable but cannot
proliferate. The number of surviving cells was then determined indirectly by MTS dye
reduction.

The

amount

of

MTS-formazan

produced

was

spectrophotometrically. Please see appendix C for a complete protocol.
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determined

In order to investigate if the linear relationship between the MTS assay and small
cell numbers found in our system holds true, HepG2 and epithelial cell lines were
trypsinized and count using hemocytometer method (Countess® Automated Cell
Counter, Invitrogen) using trypan blue staining to distinguish live cells. Different cell
densities were prepared from resuspended cell solution to allocated 5,000, 10,000,
50,000, 100,000, and 150,000 cell bodies per well plate in triplicate. Absorbance values
at 490nm using ELISA plate reader were obtained after cell cultures were exposed to
MTS reagent according to supplier protocol (Promega, CellTiter 96™ AQueous One
Solution). Results were plotted and slope was calculated linear regression analysis. The
slope relates the cell numbers to the signal provided by spectrophotometer

5.3.4 IC50 and IC90 Studies
Cell density was maintain at 20,000 cells per well and drugs were added after 24
hours, with an inkjet printer. Drugs were printed under stock solution containing 10 mg
per ml of both cytoxan and DCA. Ejected volume was control by the inkjet printing
system to print all samples in the same round. This process was done approximately in
10 min.

5.4

Results and Discussion

5.4.1 Pre-Screening Studies
Following the MTS supplier recommendation, the linear relationship between cell
number and the signal obtained from spectrophotometer was obtained for each cell type
used in the drug screening experiments. Figure 15 and 16 shows the plot for the linear
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relation between MTS absorbance reading at 490 nm. Higher concentrations were not
plotted as they do not fall under the linear phase [79]. Slopes obtained were 27,146 and
37,683 for epithelial and HegG2 cell lines, respectively.

Figure 15. Spectrophotometer signal – Epithelial cell number linear relationship. Top right data shown: slope
and r-squared value.
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Figure 16. Spectrophotometer signal – HepG2 cell number linear relationship. Top right data shown: slope
and r-squared value.

5.4.2 Proliferation Studies for Seeding Stage
A proliferation assay was performed to determine the exponential growth curves
of epithelial and HepG2 cell lines. Cell lines were seeded at 5,000, 10,000, 20,000 and
30,000 cells per well. Samples were triplicated and MTS absorbance readings were
obtained after 0, 24, 72, 120, 168 and 216 hours of culture. Results for epithelial and
HepG2 cell lines are plotted in Figure 17 and 18, respectively. Confluence was
observed to be closed to 60,000 cells per well for both cell lines. The drug screening
protocol calls for drug exposure during midline of the exponential growth. As seen from
the figures, seeding at 5,000 and 30,000 HepG2 cells per well were not good for the
drug screening protocol because a lag time was observed, which extends the assay
period on one hand, and full confluency was reached too quickly on the other hand.
However, seeding at 10,000 and 20,000 cells per well showed that appropriate
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proliferating conditions were present. Thus we chose to commence drug exposure at 72
h culture for 10,000 cells per well seeding densities and 36 h for 20,000 cells per well
seeding.

Figure 17. HepG2 semi-log proliferation curves at different cell seeding densities (5,000-30,000 cells per well).
n=3
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Figure 18. Epithelial semi-log proliferation curves at different cell seeding densities (5,000-30,000 cells per
well). n=3

5.4.3 IC 50 and IC 90 Studies using Micropipetting Technique
The survival fraction plotted in Figure 19 show that each drug regimen had
similar effect on both cell lines. Drugs were dissolved in DMSO as study reported in
appendix D found it more suitable for the screening process. Higher concentration of
cytoxan was required to inhibit growth than DCA. When exposed to cytoxan IC50 for
HepG2 and EpC was approximately 8.7 mM. When exposed to DCA IC50s were 5 and
4.35 for HepG2 and EpC, respectively. Observing the 90 percent inhibitory
concentrations, IC90s were identified as 6mM when exposed to DCA and 11.5 mM
when exposed to Cytoxan.
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Figure 19. Dose-response curves by micropipetting technique. Survival fraction of epithelial and HepG2 cell
lines under cytoxan and dichloroacetate treatment at increasing concentrations when diluted in dimethyl
sulfate oxide (DMSO). n=3. Identification of half maximal and 90% inhibitory concentrations (IC50 and IC90)

5.4.4 IC 50 and IC 90 Studies using Inkjet Printer
Initial drug stock concentrations were printed simultaneously using printer system
described before. Data resulted is reported in Appendix E. A clogging issue was
presented and as result new cartridges were used for each group sample to avoid it.
Figure 20 shows the inhibitory effect of the drugs printed at varying concentrations.
Cytoxan had same IC50 and IC90 for both cell lines, namely 9.35 and 15.65 mM,
respectively. DCA, in the other side, showed small differences of IC50 and IC90
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between cell lines. Its IC50 for epithelial cell line was 4.25 mM and for HepG2 4.75 mM.
While the IC90 for epithelial was 7mM and for HepG2 7.625 mM.

Figure 20. Dose-response curves by inkjet printing technique. Survival fraction of epithelial and HepG2 cell
lines under cytoxan and dichloroacetate treatment at increasing concentrations when diluted in dimethyl
sulfate oxide (DMSO). n=3. Identification of half maximal and 90% inhibitory concentrations (IC50 and IC90).

5.4.5 Discussion
Applying a modified inkjet printer, cancer cells along with anticancer drugs were
arrayed on a 96-well plate in such a manner that inhibition of cancer cell growth was
evaluated under various drug concentrations. The proposed platform was comparable
to standard micropipetting based screening processes.
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On the other hand, personalized medicine promises to refine diagnosis, guide
optimum treatment, and avoid unnecessary side effects. In the personalized medicine
protocol, study of patient’s cells is often needed. In particular, biopsied cancer cells can
be analyzed in an in vitro anticancer drug screening test to determine the appropriate
dosage and drug for those particular cells. To this purpose, this specific screening
platform should have several critical requirements, such as capability of multiple cell
dispensing, high-throughput, effective utilization of reagents, accuracy, etc. Inkjet
printing technology shows promising for fulfilling these requirements
Cancer chemotherapeutic drugs are often administered at their maximum
tolerated doses (MTD) to maximize the killing of malignant cells; however, the
effectiveness of this approach is limited by the collateral damage to proliferating cells in
the intestinal epithelium, bone marrow, and hair follicles [80]. Strategies similar to the
one presented can improved these side effects by better relating the most appropriate
dosage.

5.4.5.1

ICs across technologies

Table 3 shows a summary of the inhibitory concentrations obtained. It can be seen that
the IC50 concentrations are identical within uncertainty (p >0.05) across technologies..
When comparing with literature reports, Sun et al [39] reported that around 5mM of DCA
are sufficient to inhibit 50% of the cell proliferation.

Figures 21 and 22 show a

correlation plot between inkjet based and micropipetted IC 50’s and IC90’s.
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This result indicates that inkjet printing has potential to minimize screening processes
and result on similar outcomes as those elicited by higher-volumes assays
Table 3. Summary of inhibitory concentrations at 50 and 90 percent obtained by micropipetting and inkjet
printing technique.

Micropipetting
Drug

Cell
Line

Inkjet Printing

IC50 IC90 (mM) IC50 (mM) IC90 (mM)
(mM)

Delta (∆)
IC50 (mM)

IC90
(mM)

EpC

8.7

11.5

9.35

15.65

0.65

4.15

HepG2

8.7

11.5

9.35

15.65

0.65

4.15

EpC

4.35

6

4.25

7

0.10

1

HepG2

5

6

4.75

7.625

0.65

1.625

Cytoxan

DCA

Figure 21. Correlation plot for half maximal inhibitory concentrations comparing inkjet printing and manual
micropipetting techniques.
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Figure 22. Correlation plot for 90% inhibitory concentrations comparing inkjet printing and manual
micropipetting techniques.

5.4.6 Screening Process Optimization
Traditional screening process consists of many steps for the preparation of the
series of drug dilution, including drug dilution in solvents for stock concentration,
preparation of centrifugal tubes, drug serial dilution for desired concentration, secondary
dilution on culturing medium, to later duplicate, triplicate, or quadruplicate samples, plus
within the whole process is necessary to maintain suspensions homogeneous to avoid
precipitations. While robotic systems have been designed to help this biological task,
there are many disadvantages such as accumulated pipetting error, carryover, edge
effects, excessive use of disposable materials (tips, centrifugal tubes) and relative high
volume consumption.
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Inkjet printing system can alleviate issues aforementioned by a part of time
expend on preparing the required drug concentrations. Drug stock concentration was
loaded into the inkjet-headed cartridge and the highly precise volume control enables
the system to directly dispense the replicates and create immediate blends and/or
combinations to expedite the screening process. A set up time is required when direct
inkjet printing is initially implemented but for further trials the same set up can be utilize.

Figure 23. Schematic of drug screening process comparing traditional workflow and proposed direct inkjet
printing.

5.5

Conclusions
Results obtained show that both cell lines were growth inhibited under both drug

regimens.

The IC50 values obtained by micropipetting and inkjet based screening
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varied less than 1mM suggesting that the proposed screening platform closely mimics
the traditional screening outcome. However the IC90 values obtained vary in the range
of 1 to 4.5 mM. The resulted IC50 indicates that 9.35 and 4.3 mM will be sufficient to
inhibit growth of both cell lines under cytoxan and DCA treatment, respectively. In
comparison to literature, IC50 results vary based on the cell lines used for the screening
platform, but are generally in the range of 4-10 mM. Thus our results are consistent
with those that used much larger volumes, validating our hypothesis that screening
assays can be further miniaturized.
Inkjet technology shows promise to be used to determine dosages and treatment
modalities using the patient’s limited supply of biopsied cells. Expansion of the
screening process to more drugs and usage of actual patients’ biopsied cancer cells will
result in valuable data to forecast efficiency of potential drug therapies
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CHAPTER 6: PROLIFERATION OF HUMAN CELL LINES ARRAYED VIA
MODIFIED OFFICE INKJET PRINTING SYSTEMS
6.1

Abstract

Modified office inkjet printing systems have been recently introduced into bioengineering
applications demonstrating that it can precisely deposit viable biological molecules,
including DNA and mammalian cells. However, further characterization of these cells
after printing is required. The goal of this study was to characterize the proliferation of
curves of printed cells with different printing systems to understand the process effect
over cell ability to proliferate. In particular, using modified Hewlett Packard (HP) 340 and
690 models and their respective cartridges, human cell lines, HepG2 and epithelial cells
suspended in phosphate buffered saline (PBS) were dispensed over 96-well plates filled
with culturing medium (EMEM). Proliferation curves were evaluated over the period of
12 days using tetrazolium compound assay (MTS). After printing, the appearance of
both cell lines on the 96-well plate show regular cell morphology suggesting that printing
system did not affect the cell health. Cell confluency was achieved by the seventh day
after culturing for HepG2 and epithelial cells. These results suggest that mammalian
cells can be effectively delivered by a modified thermal inkjet printer onto biologicalcompatible substrates at high throughput rate. Inkjet printing technology holds potential
for creating high density arrays of living organism in an attempt to build faster and lower
volume cell-based screening experiments.
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6.2

Introduction
Recently, the inkjet printing technique has attracted much attention as a useful

tool for the fabrication of cellular patterns on substrates. In this technique, precise target
positions on a substrate can be assigned by computer-assisted deposition. Inexpensive
commercially available printers can be used in these experiments with little modification.
Several studies have shown the successful creation of cellular patterns mainly on
hydrogel substrates by using this inkjet printing technique [44-49]. There are two main
strategies, printing with living cells and printing with cell adhesion molecules [50].
Boland and coworkers reported that Chinese hamster ovary cells and primary
embryonic hippocampal or cortical cells can be directly printed onto a substrate with a
desire pattern without loss of cell function [51, 52]. The printing of cell adhesion
molecules such as collagen or cell growth/differentiation factors such as FGF-2 and
CNTF with a desired pattern onto a substrate has also been demonstrated using inkjet
printers [43, 47-49].
Inkjet printing is a non-contact reprographic technique that takes digital data from
a computer representing an image or character, and reproduces it onto a substrate
using ink drops [81]. The inkjet technology has been successfully adapted to medicine
and biomedical engineering applications, such as drug screening, genomics, and
biosensors [82-84]. Herein we study the proliferation behavior of cancerous and noncancerous cells when dispensed at low volume rates with a modified office inkjet printer.
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6.3

Materials and Methods

6.3.1 Printing Suspensions Preparation
Two cell lines were prepared including human hepatocellular carcinoma HepG2
and epithelial cell lines. One plate per cell line was trypsinized when plate confluence
reach 80% approximately. Cell pellets were collected by centrifugation (1000 rpm for 5
minutes) in a centrifugal tube. After aspirating supernatant, cells were resuspended in
Dulbecco’s phosphate buffered saline solution (DPBS) (Sigma Chemical Inc., St. Louis,
MO) to obtain cell printing suspensions. The concentration of the cell’s printing
suspension were measured through hemocytometer method using trypan blue staining
[85], cell density was kept at rate of 1,000,000 cells/ml. Cell suspensions were strained
at 40 μm to avoid agglomerations and minimize clogging of inkjet cartridge. The tubes
containing suspensions were shaken before printing, to break up clumps and ensure
good distribution. The movement of the cartridge during printing helps the cells to be
maintained mix heterogeneous. Cell suspensions prepared were added in a sterilized
cartridge and cells were dispensed at low volumetric constrains in the range of 200 to
1,000 nanoliters. Cells were manually count with the inverted microscope.

6.3.2 Inkjet Bioprinting Set up and Proliferation
HP DeskJet 340 and 690 printers and HP cartridges HP26 and HP29 were
modified with the use of the methods previously described [44]. Cartridges were filled
with 100 µl of cell printing suspensions previously prepared upon printing into 96-well
plate containing 375 µl of EMEM. Group samples were arrayed in duplicate to measure
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cell proliferation using MTS assays up to 12 days (188 hrs). Absorbance values at
490nm using ELISA plate reader were obtained after cell cultures were exposed to MTS
reagent according to supplier protocol (Promega, CellTiter 96™ AQueous One Solution)
for every other day to record proliferation curve.

6.3.3 Results and Discussion
Figure 24 shows the number of cells as function of printing volumes dispensed
by the inkjet system. It can be seen that the variation on the number of cells increases
as the volume being dispense increase. In the same way, it is observed that inkjet
printing systems have a more reliable quantity as volumes diminishes.

Figure 24. Number of cell bodies (epithelial cell line) per printed volume. n=6

We also investigated different inkjet printing system in order to utilize the most
appropriate system for cell seeding. HP 340 and HP 690 were used to eject epithelial
and HepG2 cell suspensions. A set of two samples per each day were seeded for a
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total of 12 samples. The cells were allowed to proliferate and growth curves are shown
in Figure 25 for epithelial cells and Figure 26 for HepG2. Both cell lines were printed at
same rates and as result proliferation behavior observed was different. In the case of
epithelial cells (Fig. 25) were used to compare the 340 and 690 printer systems. It was
observed that cells printed with the 340 printed system reach well confluency earlier,
around 168 hours, that the ones printed with the 690 system, around 288 hours. There
was no significant difference (p<0.05) across seeding volume for each printer system
used, suggesting that at this small volume cell growth overcomes printing volume
difference. On the other hand, printed HepG2 had a longer lag period ranging from 120
to 168 hours after seeding. In this case, higher volume printed (1,016 nl) was able to
reach confluency, however was not the same case for the lower volume printed (508 nl)
which even after 264 hour of cultivation was not able to growth.

a
b

Figure 25. Plot of inkjet printed epithelial cells using HP printer 690 (a) and HP printer 340(b). n=2
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Figure 26. Plot of inkjet printed HepG2 cells using HP printer 340. N=2

6.4

Conclusions
The HepG2 and epithelial cells were successfully printed through the nozzles of

a modified inkjet printer. The printed cells were deposited onto 96-well plates top off
with culture medium to evaluate proliferation growth for high throughput screening. The
proliferation analysis of epithelial and HepG2 cells showed that full confluency was
attained indicating that cells remain viable upon exposure to the firing mechanism used
in the inkjet printing systems. With the known benefits of high throughput and flexibility,
this technology offers researchers a cost-effective tool to rapidly develop drug screening
platforms.
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CHAPTER 7: CONCLUSIONS
An inkjet based screening platform was evaluated for capability in miniturizing
drug screening assays. We identifyied the apropiate dosage and treatment in vitro for
two cell types and two common chemotherapeutic drugs DCA and cytoxan. We have
demonstrated that this inkjet printing method can effectively deliver reliable cell and
drug volumes at level of hundreds of picoliters, 180 ± 26%.
It was proven that using the inkjet printing technology similar outcomes than the
standard micropipetting technique, in particular inhibitory concentrations IC50. However,
the similarity was not as close related for the inhibitory concentration at 90% or IC90.
While it was expected that DCA would not have as much effect on epithelial cells as in
cancerous cells we found that DCA produce apoptosis at lower concentration dosage
than commonly used chemotherapeutic drugs, cytoxan. We observed that both cell lines
were inhibited, indicating that drugs used during the screening process did not have the
selective effect towards cancerous cell bodies that was expected. Inkjet printing
technology resulted in an accurate and reproducible dispensing of the drugs onto
arrayed areas. Moreover, we observed reduced screening processing time since the
inkjetting process eliminated many of the additional steps that are necessary in
conventional screening.

7.1

Impact of the Work
Inkjet printing shows potential to reduce cost associated with the expenditure of

costly reagents and compounds compared to traditional robotic systems as shown
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shown in Table 4, In addition, the 24 h processing time can be reduced down to minutes
due to the high speed that inkjet technologies offer.
Table 4. Outcomes comparison for traditional pipette-based robotic systems and the proposed inkjet printing
platform.

Characteristic

Robotic

Printed

Mechanism

Extrusion, contact

Ink-jetting, no contact

Volume

2 µl

180 pl

Price ($)

200 (assumed)

0.018

Throughput

0.2M assays/day

18M assays/day

Screening time

24 hours (assumed)
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16 in

7.3

Future Work
Next natural work for this research is to make it a clinical reality by creating a

clinical trial with biopsied tissue samples from patients that can further benefit from the
screening platform herein described. It is well-known that chemotherapies affect rapidly
growing cells such as bone marrow, increasing the significance of predicting the
possible growth inhibition on normal and stem cell lines in order to help minimize side
effects.
In vitro studies have limited translation to clinical outcomes; therefore the design
of a platform that closely mimics the body environment is required. A possible approach
can be via creation of 3D organoids structures made of cocktail of different cells and
factors encounter in human body. Exposure of drug regimens under these conditions
will further develop the area of anticancer drug screening.
It is recommended to run a more holistic experiment where multiple drugs can be
screen over cancerous and regular primary cell lines. Along with a deeper analyst that
include synergistic, antagonistic, or additive effects. Understanding the role of the drug
exposure period is a key on screening process as the one herein described.
Direct inkjet printing has shown potential on minimizing volumes used during
screening processes to level down to picoliter; however, further development of the
technology is required to be adapted in a closer relation to the proposed application.
Development of inkjet system for regular ink printing involved challenges such as ink
formulation, substrate control, computer modulation, and development of cleaning
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stations to assure continuous function of the system. It is suggested that further
development is required in each of these areas identified to further succeed in
implementing inkjet technology into biotechnological applications.
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Appendix A: Cancer Facts

Figure 27. Incidence and mortality of selected cancers in the United Stated in 2002 [20]. Data taken from [86].
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Appendix B: DCA Controversy
In January 2007, researchers from the University Alberta published a study
showing that DCA was able to slow the growth of cancer cells from the lung, breast, and
brain in vitro [87]. This study found that laboratory rats that had DCA in their drinking
water had much slower tumor growth than those not treated with DCA. Some news and
Internet outlets reported on the study. To some, the story held out hope for a cancer
cure. The story received widespread attention, implying that an affordable, safe
treatment was available but because DCA couldn't be patented, no one would study it.
Because it is not FDA approved drug, only doctors doing research on DCA can
prescribe it. But the interest in DCA after the 2007 study led to some companies selling
DCA directly to patients over the Internet. The FDA became involved, since sellers were
marketing a drug that hadn't been proven, and that was not approved for sales or
marketing in the U.S. On those grounds, the FDA has stopped at least one shipment of
DCA from entering the United States (cancer.org).
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Appendix C: MTS Based Drug Cytotoxicity Protocol
Incubate monolayer cultures in microtitration plates in a range of drug
concentrations (Fig. 21.5). Remove the drug, and feed the plates daily for two to three
PDTs; then feed the plates again, and add MTS to each well. Incubate the plates in the
dark for 4 h, and then remove the medium and MTS. Dissolve the water-insoluble MTSformazan crystals in DMSO, add a buffer to adjust the final pH, and record the
absorbance in a plate reader.
Materials required:
Sterile:
•

Growth medium

•

Trypsin (0.25% + EDTA, 1 mM, in PBSA)

•

MTS: tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt

•

Sorensen’s glycine buffer (0.1 M glycine, 0.1 M NaCl adjusted to pH 10.5 with 1 M
NaOH)

•

Microtitration plates

•

Pipette tips, preferably in an autoclavable tip box

•

Petri dishes (non–TC-treated), 5 cm and 9 cm or reservoir (Corning)

•

Universal containers or tubes, 30 mL and 100 mL

Non-sterile:
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•

Plastic box (clear polystyrene, to hold plates)

•

Multichannel pipettor

•

Dimethyl sulfoxide (DMSO)

•

Microplate Dispenser

•

ELISA plate reader

•

Plate carrier for centrifuge (for cells growing in suspension; see Appendix II:
Microtitration Plate Centrifugation)

Procedure:
Plating out cells
1. A subconfluent monolayer culture was trypsinized, and cells were collected in
growth medium containing serum.
2. The suspension was centrifuged (5 min at 200 g) to pellet the cells. Cells were
resuspend in growth medium, and count them.
3. Cells were diluted to 2.5 to 50 × 103 cells/mL, depending on the growth rate
of the cell line, and allowing 20 mL of cell suspension per microtitration plate.
4. Transfer the cell suspension to a 9-cm Petri dish, and, with a multichannel
pipette, add 200 μL of the suspension into each well of the central 10 columns of a flatbottomed 96-well plate (80 wells per plate), starting with column 2 and ending with
column 11, placing 0.5 to 10 × 103 cells into each well.
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5. Add 200 μL of growth medium to the eight wells in columns 1 and 12. Column
1 will be used to blank the plate reader; column 12 helps maintain the humidity for
column 11 and minimizes the ‘‘edge effect.’’
6. Put the plates in a plastic lunch box, and incubate in a humidified atmosphere
at 37◦C for 1 to 3 days, such that the cells are in the exponential phase of growth at the
time that drug is added.
7. For non-adherent cells, prepare a suspension in fresh growth medium. Dilute
the cells to 5 to 100 × 103 cells/mL, and plate out only 100 μL of the suspension into
round-bottomed 96-well plates. Add drug immediately to these plates.
Drug addition
8. Prepare a serial fivefold dilution of the cytotoxic drug in growth medium to give eight
concentrations. This set of concentrations should be chosen such that the highest
concentration kills most of the cells and the lowest kills none of the cells. Once the
toxicity of a drug is known, a smaller range of concentrations can be used. Normally
three plates are used for each drug to give triplicate determinations within one
experiment.
9. For adherent cells:
(a) Remove the medium from the wells in columns 2 to 11. This can be achieved
with a hypodermic needle attached to a suction line.
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(b) Feed the cells in the eight wells in columns 2 and 11 with 200 μL of fresh growth
medium; these cells are the controls.
(c) Transfer the drug solutions to 5-cm Petri dishes, and add 200 μL to each group of
four wells with a four-tip pipettor.
(d) Add the cytotoxic drug to the cells in columns 3 to 10. Only four wells are needed
for each drug concentration, such that rows A through D can be used for one drug
and rows E through H for a second drug.
10. Return the plates to the plastic box, and incubate them for a defined exposure
period.
Growth period
11. At the end of the drug exposure period, remove the medium from all of the wells
containing cells, and feed the cells with 200 μL of fresh medium. Centrifuge plates
containing non-adherent cells (5 min at 200 g) to pellet the cells. Then remove the
medium, using a fine-gauge needle to prevent disturbance of the cell pellet.
12. Feed the plates daily for 2 to 3 PDTs. Estimation of surviving cell numbers
13. Feed the plate with 200 μL of fresh medium at the end of the growth period, and add
50 μL of MTS to all of the wells in columns 1 to 11.
14. Wrap the plates in aluminum foil, and incubate them for 4 h in a humidified
atmosphere at 37º C. Note that 4 h is a minimum incubation time, and plates can be
left for up to 8 h.
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15. Remove the medium and MTS from the wells (centrifuge for non-adherent cells),
and dissolve the remaining MTS-formazan crystals by adding 200 μL of DMSO to all
of the wells in columns 1 to 11.
16. Add glycine buffer (25 μL per well) to all of the wells containing DMSO.
17. Record absorbance at 490 nm immediately, because the product is unstable. Use
the wells in column 1, which contain medium and MTS but no cells, to blank the
plate reader.

A

B

From no drug
to 15 ug/ml

Figure 28. A) Semi-log plot of standard dose-response curve. B) Microtitration assay on 96-well plate.
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Appendix D: Drug Solvent Analysis and Inhibitory Concentration for
Drug Screening Process
The inhibitory effect of cells exposed to cyclophosphamide monohydrate and
dichloroacetate (DCA) at a concentration of 10.563 and 5.157 mM is shown in Figure
29. It was found that when the drugs were dissolved in PBS no inhibitory effect was
observed, suggesting drugs insolubility in PBS. As expected, DMSO-dissolved drugs
inhibited cell growth at approximately 50 percent when concentrations were 10.563 mM
in cytoxan and 5.157 mM in DCA.

Figure 29. Number of cells per well when exposed to cyclophosphamide monohydrate and dichloroacetate
(DCA) at a concentration of 10.563 and 5.157 mM, respectively. DMSO and PBS were used as drug solvents,
controls in the far right report data on cytotoxicity when exposed to only medium (EMEM), 1% PBS in EMEM,
and 1% DMSO in EMEM. n=3
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The lack of any gradient on the dose-response curve when drugs were dissolved
in PBS indicates a solubility problem of the PBS with used chemotherapeutic drugs.
Therefore, PBS was not a suitable solvent for the drugs herein investigated.

Figure 30. Dose-response curves by micropipetting technique. Survival fraction of epithelial and HepG2 cell
lines under Cytoxan and dichloroacetate treatment at increasing concentrations when diluted in phosphate
buffer saline (PBS). n=3
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Appendix E: Drug Screening using Inkjet printing – Single Round
Figure 31 show the survival fraction of cells after drug exposure. A hill around
4mM was observed for cell lines exposed to DCA, while for cell lines exposed to
cytoxan the hill was around 6mM.

These observations were expected and were

reported before in the literature[39]. At higher concentrations, the data suggest that
inhibition was increasing with dosage; however, at further increased concentrations, the
cells fully recovered. This suggests that the inkjet nozzles may have been clogged.
Printing direction is illustrated by arrow located at bottom of Figure 31.

Figure 31. Dose-response curves by inkjet printing technique. Survival fraction of epithelial and HepG2 cell
lines under cytoxan and dichloroacetate treatment at increasing concentrations when diluted in dimethyl
sulfate oxide (DMSO). n=3. Identification of half maximal and 90% inhibitory concentrations (IC50 and IC90).
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